Correction: Arce-Huamani et al. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. <i>Medicina</i> 2023, <i>59</i>, 1867

Correction: Arce-Huamani et al. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. <i>Medicina</i> 2023, <i>59</i>, 1867

There was an error in the original publication [...]

Bibliographic Details
Main Authors:	Miguel A. Arce-Huamani, Joshuan J. Barboza, José Fabián Martínez-Herrera, J. Smith Torres-Roman, Jorge L. Maguiña
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Medicina
Subjects:	n/a
Online Access:	https://www.mdpi.com/1648-9144/60/1/134

Similar Items

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
by: Miguel A. Arce-Huamani, et al.
Published: (2023-10-01)

Management of venous thromboembolism in patients with cancer: role of dalteparin
by: Lori-Ann Linkins
Published: (2008-04-01)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
by: Javier Trujillo‐Santos, et al.
Published: (2022-05-01)

Comment on Muth et al. Assessing Critical Flicker Fusion Frequency: Which Confounders? A Narrative Review. <i>Medicina</i> 2023, <i>59</i>, 800
by: Natalia D. Mankowska, et al.
Published: (2023-09-01)

Retrospective study evaluating safety, clinical effect, and dosing of dalteparin for the treatment of venous thromboembolism in term neonates
by: Sherman, N, et al.
Published: (2024)

Reply to Mankowska et al. Comment on “Muth et al. Assessing Critical Flicker Fusion Frequency: Which Confounders? A Narrative Review. <i>Medicina</i> 2023, <i>59</i>, 800”
by: Thomas Muth, et al.
Published: (2023-10-01)

Comment on Marra et al. Metastatic Renal Cell Carcinoma to the Soft Tissue 27 Years after Radical Nephrectomy: A Case Report. <i>Medicina</i> 2023, <i>59</i>, 150
by: Pietro De Luca, et al.
Published: (2023-02-01)

CURRENT TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS WITH ANTICOAGULANTS: APIXABAN
by: I. S. Yavelov
Published: (2015-12-01)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
by: Trkulja V
Published: (2016-02-01)

Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
by: Antonijević Nebojša, et al.
Published: (2020-01-01)

RETRACTED: Dewi et al. Efficacy of Intermittent and Continuous Subglottic Secretion Drainage in Preventing the Risk of Ventilator-Associated Pneumonia: A Meta-Analysis of Randomized Control Trials. <i>Medicina</i> 2023, <i>59</i>, 283
by: Yulis Setiya Dewi, et al.
Published: (2023-10-01)

<i>Anax panybeus</i> Hagen, 1867: an addition to the Odonata (Aeshnidae) of India
by: T.R. Mitra, et al.
Published: (2013-02-01)

ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
by: Stephan V. Hendriks, et al.
Published: (2020-04-01)

Reply to De Luca et al. Comment on “Marra et al. Metastatic Renal Cell Carcinoma to the Soft Tissue 27 Years after Radical Nephrectomy: A Case Report. <i>Medicina</i> 2023, <i>59</i>, 150”
by: Carmine Alfano, et al.
Published: (2023-04-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015-12-01)

Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism
by: O. V. Averkov, et al.
Published: (2019-01-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015-12-01)

Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer
by: E. P. Panchenko
Published: (2020-06-01)

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
by: Sofia Attelind, et al.
Published: (2022-09-01)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
by: Zalpour A, et al.
Published: (2014-11-01)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
by: Werth S, et al.
Published: (2012-03-01)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
by: Dranitsaris G, et al.
Published: (2017-01-01)

Montoya Huamaní, Segundo (2018). Conﬂictos de interpretación en torno al marxismo de Mariátegui. Lima: Heraldos Editores.
by: Mirko Díaz Sánchez
Published: (2018-12-01)

Libanius the Historian? Praise and the Presentation of the Past in <i>Or.</i> 59
by: Alan J. Ross
Published: (2016-05-01)

Effects of Dalteparin on Structure of Hippocampal Neurons of Rats in Chronic Stress
by: Mansoureh Soleimani, et al.
Published: (2012-07-01)

Effects of dalteparin on structure of hippocampal neurons of rats in chronic stress
by: Fereshteh Farajdokht, et al.
Published: (2012-07-01)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
by: Sara Reda, et al.
Published: (2022-05-01)

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
by: Lisa A. de Jong, et al.
Published: (2018-07-01)

2023: Núm. 59 - nov
by: Observatori de Bioètica i Dret
Published: (2023-10-01)

On the (29,5)-Arcs in <i>PG</i>(2,7) and Some Generalized Arcs in <i>PG</i>(2,<i>q</i>)
by: Iliya Bouyukliev, et al.
Published: (2020-03-01)

Inhibition of trypsin by heparin and dalteparin, a low molecular weight heparin
by: OLIVERA M. BOSNIĆ, et al.
Published: (2009-04-01)

Inhibition of trypsin by heparin and dalteparin, a low molecular weight heparin
by: Bosnić Olivera M., et al.
Published: (2009-01-01)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
by: Alexander Cohen, et al.
Published: (2021-01-01)

Cardiac Calcified Amorphous Tumor Presenting with Thromboembolism in a Patient Under Apixaban Treatment
by: Tufan ÇINAR, et al.
Published: (2022-02-01)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
by: Robert Frank Cornell, et al.
Published: (2019-02-01)

Dalmacija i banska Hrvatska u Pavlinovićevim Putima (Godine 1867–75)
by: Krystyna Pieniążek-Marković
Published: (2020-03-01)

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial
by: Xianchen Liu, et al.
Published: (2015-12-01)